Merck & Co. Inc. has announced the initiation of the EXPrESSIVE Phase 3 clinical trials to evaluate the safety and efficacy of MK-8527, an investigational once-monthly oral nucleoside reverse transcriptase translocation inhibitor for HIV pre-exposure prophylaxis (PrEP). The trials are being conducted in collaboration with the Gates Foundation. The EXPrESSIVE-10 trial will focus on women and adolescent girls in sub-Saharan Africa, while the EXPrESSIVE-11 trial will target individuals with a greater likelihood of HIV-1 exposure in 16 countries, with enrollment scheduled to begin in August 2025. This decision follows a Phase 2 trial involving 350 participants, which demonstrated favorable safety and pharmacokinetic profiles of MK-8527. Results from this Phase 2 trial were presented during the 13th International AIDS Society Conference on HIV Science in Kigali, Rwanda.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。